Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > IL-17 blocker: effective and safe in patients with comorbidities

IL-17 blocker: effective and safe in patients with comorbidities

EADV 2019

An analysis of psoriasis patients with comorbidities included in four phase 3 trials showed that secukinumab exhibits a comparable efficacy and safety in patients with comorbidities at baseline [1].

Today, psoriasis is seen as a chronic inflammatory systemic disease. Research has shown that different comorbidities commonly found in patients with psoriasis, such as arthritis, depression, inflammatory bowel disease, and cardiovascular diseases, are directly related to the chronic inflammatory status of psoriasis, and may thus influence efficacy and safety of drug treatment [2].

The IL-17 blocker secukinumab has demonstrated long-lasting efficacy and safety in the complete spectrum of manifestations of psoriatic disease. An analysis of pooled data from four phase 3 trials (i.e. ERASURE, FIXTURE, FEATURE, and JUNCTURE) assessed the incremental burden of comorbidities on clinical efficacy and safety among patients with moderate-to-severe psoriasis.

A total of 880 ...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on